AVM v1, released 02-OCT-22

A manually curated database of aerosol-transmitted virus mutations, human diseases, and drugs

Mutation detail:


Mutation site E484Q
Virus SARS-CoV-2
Mutation level Amino acid level
Gene/protein/region type S
Gene ID 43740568
Country France
Mutation type nonsynonymous mutation
Genotype/subtype/clade 20I
Sample Human
Variants -
Viral reference sequence NC 045512.2
Drug/antibody/vaccine bamlanivimab resistant
Transmissibility -
Transmission mechanism -
Pathogenicity -
Pathogenicity mechanism -
Immune escape mutation Yes
Immune escape mechanism -
RT-PCR primers probes -

Protein detail:


Protein name Spike glycoprotein
Uniprot protein ID P0DTC2
Protein length 1273 amino acids
Protein description Spike protein is one of the structural proteins of SARS-CoV-2. The monomeric protein consists of one large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail at C-terminus. It encompasses 22 glycosylation sites. S protein cleaves into two subunits namely S1 and S2 following receptor recognition. Receptor Binding Domain (RBD) in S1 subunit plays a major role in ACE2 receptor binding.

Literature information:


Pubmed ID 34352197
Clinical information No
Disease -
Published year 2021
Journal EMERGING INFECTIOUS DISEASES
Title SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy
Author Aurelie Truffot, Julien Andreani, Marion Le Marechal, Alban Caporossi, Olivier Epaulard
Evidence This analysis detected clade 20I/501Y.V1, Alpha variant (Pangolin: B.1.1.7), on day 3 in nasopharyngeal swab specimens. Three days later (day 6), a novel mutation (G23012C, S: E484Q) appeared in nasopharyngeal swab specimens at frequency of 82%, which rapidly reached >99% (S: E484Q) 10 days after mAb treatment (Table; Figure). Eleven days after the mAb infusion, we detected an additional nucleotide mutation A23040G (S: Q493R) in only a blood sample at a frequency of 64%. This rate reached 76% at day 17 without any detection in nasopharyngeal swab specimens.